Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
The EMA approved storing and shipping Wegovy at up to 30°C (86°F) for 48 hours, making it the first GLP-1 injection with room-temperature delivery flexibility in Europe. In other news, Vivatides raised $54M for RNA therapies and Gilead exercised its option on Kymera Therapeutics.
What This Means for You
The EMA approved storing and shipping Wegovy at up to 30°C (86°F) for 48 hours, making it the first GLP-1 injection with room-temperature delivery flexibility in Europe. In other news, Vivatides raised $54M for RNA therapies and Gilead exercised its option on Kymera Therapeutics.
Three stories from the GLP-1 and pharma world this week, but one matters more to patients than the other two.
The consumer-relevant headline: the European Medicines Agency approved storing and shipping Wegovy at temperatures up to 30°C (86°F) for 48 hours. That makes Wegovy the first GLP-1 injection with this kind of delivery flexibility in the EU. Until now, semaglutide pens needed continuous refrigeration during shipping, which created headaches for mail-order pharmacies and patients receiving deliveries in warm climates. If you’ve ever worried about your GLP-1 pen sitting on a hot doorstep, this is the kind of regulatory change that actually affects your daily life.
This approval only applies to the EU for now. U.S. labeling for Wegovy still requires refrigeration at 2°C to 8°C (36°F to 46°F) until the use-by date, with room temperature storage up to 30°C allowed for only 28 days after first use. If the FDA follows the EMA’s lead, U.S. patients could see similar shipping flexibility, which would be especially welcome during summer months when temperature excursions during delivery are common. For now, if you’re a U.S. patient ordering through providers like Ro or Noom Med, keep following the current cold-chain guidelines on your packaging.
In biotech funding news, Vivatides raised $54 million in a Series A round for extrahepatic RNA therapies. These are treatments delivered outside the liver, which is relevant to the broader obesity and metabolic disease pipeline but years from clinical application. Separately, Gilead exercised its option on Kymera Therapeutics, a deal focused on targeted protein degradation. Neither of these developments affects GLP-1 availability or pricing today, but they signal continued investment in next-generation metabolic therapies.
The pattern across all three stories is the same: the obesity treatment space is attracting money, regulatory attention, and infrastructure improvements at a pace we haven’t seen before. If you’re currently on a GLP-1 or considering one, the logistics of getting and storing your medication are actively getting better, even if it’s happening faster in Europe than in the U.S. right now.
Source: Endpoints News
Frequently asked questions
Does the EU cold chain change affect U.S. patients?
Not yet. The EMA approval for room-temperature Wegovy shipping applies only to the European Union. U.S. labeling still requires refrigeration during storage and shipping, with room temperature allowed for up to 28 days once the pen is in use. Novo Nordisk could submit similar data to the FDA, but there’s no public timeline for that. For now, U.S. patients should continue following the storage instructions on their Wegovy packaging.
How should I handle GLP-1 deliveries in hot weather?
If you receive GLP-1 medications by mail, check the package immediately on delivery. Most pharmacies ship with insulated packaging and cold packs, but temperature excursions can happen during summer months. If the pen feels warm or the cold pack is completely melted, contact your pharmacy before using it. Some patients request signature-required delivery to avoid pens sitting outside. Providers like Hims and Ro that ship directly often include temperature indicators in their packaging.
What is Vivatides and should I care about it?
Vivatides is an early-stage biotech developing RNA-based therapies that can be delivered outside the liver. This is technically interesting because most RNA drugs today only work in liver cells. If Vivatides succeeds, it could eventually enable RNA-based obesity treatments that target muscle, fat, or brain tissue directly. But this is Series A funding, meaning the company is years away from clinical trials and a decade or more from having a product you could use. File it under “interesting pipeline” rather than anything actionable.
Keep reading
Frequently Asked Questions
Does the EU cold chain change affect U.S. patients?
How should I handle GLP-1 deliveries in hot weather?
What is Vivatides and should I care about it?
Original source
Read the full article at Endpoints News